143 related articles for article (PubMed ID: 15614187)
1. Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
Peñuelas S; Noé V; Morales R; Ciudad CJ
Med Sci Monit; 2005 Jan; 11(1):BR6-12. PubMed ID: 15614187
[TBL] [Abstract][Full Text] [Related]
2. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells.
Peñuelas S; Noé V; Ciudad CJ
FEBS J; 2005 Feb; 272(3):696-710. PubMed ID: 15670151
[TBL] [Abstract][Full Text] [Related]
3. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
4. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
5. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
6. [cDNA microarray analysis of gene expression in acquired methotrexate-resistant of human choriocarcinoma].
Chen YX; Xie X; Cheng Q
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):396-9. PubMed ID: 15312324
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Selga E; Noé V; Ciudad CJ
Biochem Pharmacol; 2008 Jan; 75(2):414-26. PubMed ID: 17945194
[TBL] [Abstract][Full Text] [Related]
8. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
Takebe N; Zhao SC; Adhikari D; Mineishi S; Sadelain M; Hilton J; Colvin M; Banerjee D; Bertino JR
Mol Ther; 2001 Jan; 3(1):88-96. PubMed ID: 11162315
[TBL] [Abstract][Full Text] [Related]
9. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance.
Braun SE; McIvor RS; Davidson AS; Hanna M; Traycoff CM; Berebetsky DA; Gonin R; Broxmeyer HE; Cornetta K
Cancer Gene Ther; 1997; 4(1):26-32. PubMed ID: 9012448
[TBL] [Abstract][Full Text] [Related]
10. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F
Biochem Pharmacol; 2009 Apr; 77(8):1410-7. PubMed ID: 19426680
[TBL] [Abstract][Full Text] [Related]
12. [Double-mutant dihydrofolate reductase gene transfection into bone marrow cells protects mice from chemotherapy].
Gao HD; Lu P; Lu Y; Pang K; Xu HM; Wang SB; Chen JQ; Zhao SC
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):583-5. PubMed ID: 17236551
[TBL] [Abstract][Full Text] [Related]
13. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase.
Volpato JP; Fossati E; Pelletier JN
J Mol Biol; 2007 Oct; 373(3):599-611. PubMed ID: 17868689
[TBL] [Abstract][Full Text] [Related]
14. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.
James R; May C; Diers M; Wagner J; McIvor R
Bone Marrow Transplant; 1999 Oct; 24(8):815-21. PubMed ID: 10516690
[TBL] [Abstract][Full Text] [Related]
16. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
Lindgren M; Rosenthal-Aizman K; Saar K; Eiríksdóttir E; Jiang Y; Sassian M; Ostlund P; Hällbrink M; Langel U
Biochem Pharmacol; 2006 Feb; 71(4):416-25. PubMed ID: 16376307
[TBL] [Abstract][Full Text] [Related]
17. Resistance mechanisms to methotrexate in tumors.
Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells.
Morales C; Ribas M; Aiza G; Peinado MA
Oncogene; 2005 Oct; 24(45):6842-7. PubMed ID: 16007155
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis for the identification of proteins related to methotrexate resistance.
Feng YX; Bai J; Zhang CY; Fu SB
Yi Chuan Xue Bao; 2006 May; 33(5):391-6. PubMed ID: 16722333
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]